Comparison of Clinical Efficacy of Intravitreal Ranibizumab with and without Triamcinolone Acetonide in Macular Edema Secondary to Central Retinal Vein Occlusion

医学 丙酮 眼科 黄斑水肿 血管抑制剂 视网膜中央静脉阻塞 曲安奈德 视力 视网膜分支静脉阻塞 闭塞 视网膜 外科 贝伐单抗 化疗
作者
Chuanfeng Fan,Yu Wang,Qiang Ji,Bojun Zhao,Juan Xie
出处
期刊:Current Eye Research [Taylor & Francis]
卷期号:39 (9): 938-943 被引量:12
标识
DOI:10.3109/02713683.2014.885533
摘要

Purpose: To compare visual outcomes and spectral-domain optical coherence tomography results following treatment with intravitreal ranibizumab (IVR) or IVR combined with intravitreal triamcinolone acetonide (IVTA) for macular edema (ME) secondary to central retinal vein occlusion (CRVO).Methods: This prospective, case-controlled study examined 57 eyes (57 patients) with ME secondary to CRVO, which were treated with IVR (0.5 mg, n = 30 eyes) or IVR (0.5 mg) and IVTA (1 mg, n = 27 eyes) as the initial therapy. Further intravitreal treatment was administered as necessary.Results: All 57 patients completed at least 6 months of follow-up. At baseline, mean ( ± standard error) best-corrected visual acuity (BCVA) was 45.8 ± 23.2 letters in the IVR group and 47.3 ± 19.3 letters in the IVR + IVTA group (p = 0.790). Significant improvement in BCVA over baseline was observed in both groups at all six study visits (IVR group: p = 0.0003, 0.0001, 0.0018, 0.0145, 0.0107, 0.005; IVR + IVTA group: p = 0.0001, 0.0001, 0.0004, 0.0068, 0.0007, 0.0002), with no significant BCVA differences between groups. Significant reduction in mean central subfield thickness, compared with baseline, was also observed in both groups at all six study visits (IVR group, p = 0.0001; IVR + IVTA group, p = 0.0001), with no significant difference between groups in the magnitude of macular thickness reduction. The mean number of injections was significantly higher (p = 0.0001) in the IVR group (4.23 ± 0.56) than in the IVR + IVTA group (3.42 ± 0.41).Conclusions: Treating ME secondary to CRVO with IVR or IVR + IVTA had similar effects on central macular thickness and BCVA in patients with ME secondary to CRVO over a 6-month follow-up period. The mean number of intravitreal injections was higher in the IVR group than in the IVR + IVTA group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FXY发布了新的文献求助10
1秒前
Zzz呀发布了新的文献求助10
1秒前
花楸树发布了新的文献求助10
2秒前
是苗苗丫完成签到,获得积分10
2秒前
高宇晖完成签到,获得积分10
3秒前
zz完成签到 ,获得积分10
3秒前
感动的煜城完成签到,获得积分10
3秒前
3秒前
HITvagary完成签到,获得积分10
3秒前
张小兔啊完成签到,获得积分10
3秒前
呀呀呀完成签到,获得积分10
3秒前
xl完成签到 ,获得积分10
4秒前
4秒前
啦啦啦完成签到,获得积分10
4秒前
Moonlight发布了新的文献求助10
4秒前
vickyyao完成签到,获得积分10
4秒前
杨杨杨完成签到,获得积分10
6秒前
shanshan发布了新的文献求助10
6秒前
6秒前
ding应助科研通管家采纳,获得10
6秒前
思源应助科研通管家采纳,获得10
6秒前
6秒前
今后应助科研通管家采纳,获得10
7秒前
科研通AI6应助科研通管家采纳,获得30
7秒前
科研通AI5应助科研通管家采纳,获得10
7秒前
烟花应助科研通管家采纳,获得10
7秒前
FashionBoy应助科研通管家采纳,获得10
7秒前
小马甲应助科研通管家采纳,获得10
7秒前
7秒前
7秒前
ding应助科研通管家采纳,获得10
7秒前
7秒前
文静的天蓝完成签到,获得积分10
7秒前
NexusExplorer应助科研通管家采纳,获得10
7秒前
陈早早完成签到,获得积分10
7秒前
7秒前
赘婿应助科研通管家采纳,获得10
7秒前
无花果应助科研通管家采纳,获得10
7秒前
香蕉觅云应助科研通管家采纳,获得10
7秒前
HahaNana应助科研通管家采纳,获得20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
网络安全 SEMI 标准 ( SEMI E187, SEMI E188 and SEMI E191.) 1000
计划经济时代的工厂管理与工人状况(1949-1966)——以郑州市国营工厂为例 500
INQUIRY-BASED PEDAGOGY TO SUPPORT STEM LEARNING AND 21ST CENTURY SKILLS: PREPARING NEW TEACHERS TO IMPLEMENT PROJECT AND PROBLEM-BASED LEARNING 500
Why America Can't Retrench (And How it Might) 400
Two New β-Class Milbemycins from Streptomyces bingchenggensis: Fermentation, Isolation, Structure Elucidation and Biological Properties 300
Modern Britain, 1750 to the Present (第2版) 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4614444
求助须知:如何正确求助?哪些是违规求助? 4018649
关于积分的说明 12439260
捐赠科研通 3701425
什么是DOI,文献DOI怎么找? 2041187
邀请新用户注册赠送积分活动 1073927
科研通“疑难数据库(出版商)”最低求助积分说明 957600